InhA, a target of the antituberculous drug isoniazid, is involved in a mycobacterial fatty acid elongation system, FAS-II

References

1. Banerjee A., Dubnau E., Quémard A., Balasubramanian V., Um K. S., Wilson T., Collins D., de Lisle G., Jacobs W. R. Jr 1994; InhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263:227–230 [CrossRef]
   [Google Scholar]
2. Banerjee A., Sugantino M., Sacchettini J. C., Jacobs W. R. Jr 1998; The mabA gene from the inhA operon of Mycobacterium tuberculosis encodes a 3-ketoacyl reductase that fails to confer isoniazid resistance. Microbiology 144:2697–2704 [CrossRef]
   [Google Scholar]
3. Bardou F., Quémard A., Dupont M. A., Horn C., Marchal G., Daffé M. 1996; Effects of isoniazid on the ultrastructure of Mycobacterium aurum and Mycobacterium tuberculosis and on the production of secreted proteins. Antimicrob Agents Chemother 40:2459–2467
   [Google Scholar]
4. Bardou F., Raynaud C., Ramos C., Lanéelle M. A., Lanéelle G. 1998; Mechanism of isoniazid uptake in Mycobacterium tuberculosis. Microbiology 144:2539–2544 [CrossRef]
   [Google Scholar]
5. Basso L. A., Zheng R., Musser J. M., Jacobs W. R. Jr, Blanchard J. S. 1998; Mechanisms of isoniazid resistance in Mycobacterium tuberculosis: enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates. J Infect Dis 178:769–775 [CrossRef]
   [Google Scholar]
6. Bloch K. 1977; Control mechanisms for fatty acid synthesis in Mycobacterium smegmatis. Adv Enzymol 45:1–84
   [Google Scholar]
7. Cole S. T., Brosch R., Parkhill J.39 other authors 1998; Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393:537–544 [CrossRef]
   [Google Scholar]
8. Daffé M., Draper P. 1998; The envelope layers of mycobacteria with reference to their pathogenicity. Adv Microb Physiol 39:131–203
   [Google Scholar]
9. Dessen A., Quémard A., Blanchard J. S., Jacobs W. R. Jr, Sacchettini J. C. 1995; Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis. Science 267:1638–1641 [CrossRef]
   [Google Scholar]
10. Dubnau E., Lanéelle M. A., Soares S., Bénichou A., Vaz T., Promé D., Promé J. C., Daffé M., Quémard A. 1997; Mycobacterium bovis BCG genes involved in the biosynthesis of cyclopropyl keto- and hydroxy-mycolic acids. Mol Microbiol 23:313–322 [CrossRef]
    [Google Scholar]
11. Dubnau E., Marrakchi H., Smith I., Daffé M., Quémard A. 1998; Mutations in the cmaB gene are responsible for the absence of methoxymycolic acid in Mycobacterium bovis BCG Pasteur. Mol Microbiol 29:1526–1528
    [Google Scholar]
12. George K. M., Yuan Y., Sherman D. R., Barry C. E. 1995; The biosynthesis of cyclopropanated mycolic acids in Mycobacterium tuberculosis. J Biol Chem 270:27292–27298 [CrossRef]
    [Google Scholar]
13. Harwood J. L. 1986; Lipid metabolism. In The Lipid Handbook pp. 485–525Edited by Gunstone F. D., Harwood J. L., Padley F. B. London & New York: Chapman & Hall;
    [Google Scholar]
14. Kapur V., Li L. L., Hamrick M. R.10 other authors 1995; Rapid Mycobacterium species assignment and unambiguous identification of mutations associated with antimicrobial resistance in Mycobacterium tuberculosis by automated DNA sequencing. Arch Pathol Lab Med 119:131–138
    [Google Scholar]
15. Kikuchi S., Kusaka T. 1982; New malonyl-CoA-dependent fatty acid elongation system in Mycobacterium smegmatis. J Biochem 92:839–844
    [Google Scholar]
16. Kolattukudy P. E., Fernandes N. D., Azad A. K., Fitzmaurice A. M., Sirakova T. D. 1997; Biochemistry and molecular genetics of cell-wall lipid biosynthesis in mycobacteria. Mol Microbiol 24:263–270 [CrossRef]
    [Google Scholar]
17. Lacave C., Quémard A., Lanéelle G. 1990; Cell-free synthesis of mycolic acids in Mycobacterium aurum: radioactivity distribution in newly synthesized acids and presence of cell wall in the system. Biochim Biophys Acta 1045:58–68 [CrossRef]
    [Google Scholar]
18. Lan é elle G. 1989; Mycolic acid metabolism: biosynthesis of complex lipids. Acta Leprol 7: (Suppl. 1)65–73
    [Google Scholar]
19. Mdluli K., Slayden R. A., Zhu Y. Q., Ramaswamy S., Pan X., Mead D., Crane D. D., Musser J. M., Barry C. E. 1998; Inhibition of a Mycobacterium tuberculosis β-ketoacyl-ACP synthase by isoniazid. Science 280:1607–1610 [CrossRef]
    [Google Scholar]
20. Middlebrook G. 1952; Sterilization of tubercle bacilli by isonicotinic acid hydrazide and the incidence of variants resistant to the drug in vitro. Am Rev Tuberc 65:765–767
    [Google Scholar]
21. Musser J. M., Kapur V., Williams D. L., Kreiswirth B. N., van Soolingen D., van Embden J. D. A. 1996; Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. J Infect Dis 173:196–202 [CrossRef]
    [Google Scholar]
22. Odriozola J. M., Bloch K. 1977; Effects of phosphatidylcholine liposomes on the fatty acid synthetase complex from Mycobacterium smegmatis. Biochim Biophys Acta 488:198–206 [CrossRef]
    [Google Scholar]
23. Odriozola J. M., Ramos J. A., Bloch K. 1977; Fatty acid synthetase activity in Mycobacterium smegmatis: characterization of the acyl carrier protein-dependent elongating system. Biochim Biophys Acta 488:207–217 [CrossRef]
    [Google Scholar]
24. Quémard A., Lacave C., Lanéelle G. 1991; Isoniazid inhibition of mycolic acid synthesis by cell free extracts of sensitive and resistant strains of Mycobacterium aurum. Antimicrob Agents Chemother 35:1035–1039 [CrossRef]
    [Google Scholar]
25. Quémard A., Sacchettini J. C., Dessen A., Vilchèzes C., Bittman R., Jacobs W. R. Jr, Blanchard J. S. 1995; Enzymatic characterization of the target for isoniazid in Mycobaterium tuberculosis. Biochemistry 34:8235–8241 [CrossRef]
    [Google Scholar]
26. Quémard A., Dessen A., Sugantino M., Jacobs W. R. Jr, Sacchettini J. C., Blanchard J. S. 1996; Binding of catalase-peroxidase-activated isoniazid to wild-type and mutant Mycobacterium tuberculosis enoyl-ACP reductases. J Am Chem Soc 118:1561–1562 [CrossRef]
    [Google Scholar]
27. Qureshi N., Sathyamoorthy N., Takayama K. 1984; Biosynthesis of C₃₀ to C₅₆ fatty acids by an extract of Mycobacterium tuberculosis H37Ra. J Bacteriol 157:46–52
    [Google Scholar]
28. Ristow M., Mohlig M., Rifai M., Schatz H., Feldmann K., Pfeiffer A. 1995; New isoniazid/ethionamide resistance gene mutation and screening for multidrug-resistant Mycobacterium tuberculosis strains. Lancet 346:502–503
    [Google Scholar]
29. Rozwarski D. A., Grant G. A., Barton D. H. R., Jacobs W. R. Jr, Sacchettini J. C. 1998; Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 279:98–102 [CrossRef]
    [Google Scholar]
30. Shimakata T., Fujita Y., Kusaka T. 1977; Acetyl-CoA-dependent elongation of fatty acids in Mycobacterium smegmatis. J Biochem 82:725–732
    [Google Scholar]
31. Slayden R. A., Lee R. E., Armour J. W., Cooper A. M., Orme I. M., Brennan P. J., Besra G. S. 1996; Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid and mycolic acid synthesis. Antimicrob Agents Chemother 40:2813–2819
    [Google Scholar]
32. Snider D. E., Raviglione M., Kochi A. 1994; Global burden of tuberculosis. In Tuberculosis: Pathogenesis, Protection, and Control pp. 3–11Edited by Bloom B. R. Washington, DC: American Society for Microbiology;
    [Google Scholar]
33. Takayama K., Qureshi N. 1984; Structure and synthesis of lipids. In The Mycobacteria, a Source Book pp. 315–344Edited by Kubica G. P., Wayne L. G. New York, NY: Marcel Dekker;
    [Google Scholar]
34. Takayama K., Wang L., David H. L. 1972; Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2:29–35 [CrossRef]
    [Google Scholar]
35. Wheeler P. R., Anderson P. M. 1996; Determination of the primary target for isoniazid in mycobacterial mycolic acid biosynthesis with Mycobacterium aurum A⁺. Biochem J 318:451–457
    [Google Scholar]
36. Winder F. G. 1982; Mode of action of the antimycobacterial agents. In The Biology of the Mycobacteria pp. 353–438Edited by Ratledge C., Stanford J. London: Academic Press;
    [Google Scholar]
37. World Health Organization 1997 Anti-tuberculosis drug resistance in the world: the WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance Geneva: WHO Global Tuberculosis Programme;
    [Google Scholar]
38. Yasaka Y., Tanaka M., Shono T., Tetsumi T., Katakawa J. 1990; 2-(2,3-Naphthalimino)ethyl trifluoromethanesulphonate as a highly reactive ultraviolet and fluorescent labelling agent for the liquid chromatographic determination of carboxylic acids. J Chromatogr 508:133–140 [CrossRef]
    [Google Scholar]
39. Yuan Y., Lee R. E., Besra G. S., Belisle J. T., Barry C. E. 1995; Identification of a gene involved in the biosynthesis of cyclopropanated mycolic acids in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 92:6630–6634 [CrossRef]
    [Google Scholar]
40. Zabinski R. F., Blanchard J. S. 1997; The requirement for manganese and oxygen in the isoniazid-dependent inactivation of Mycobacterium tuberculosis enoyl reductase. J Am Chem Soc 119:2331–2332 [CrossRef]
    [Google Scholar]